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To determine how to set optimal oral L-serine (serine) dose levels for a clinical trial, existing
literature was surveyed. Data sufficient to set the dose was inadequate, and so an (n  10)
phase I-A calibration trial was performed, administering serine with and without other oral
agents. We analyzed the trial and the literature data using pharmacokinetic (PK) modeling
and statistical analysis. The therapeutic goal is to modulate specific serine-related
metabolic pathways in the liver using the lowest possible dose which gives the desired
effect since the upper bound was expected to be limited by toxicity. A standard PK
approach, in which a common model structure was selected using a fit to data, yielded a
model with a single central compartment corresponding to plasma, clearance from that
compartment, and an endogenous source of serine. To improve conditioning, a parametric
structure was changed to estimate ratios (bioavailability over volume, for example). Model
fit quality was improved and the uncertainty in estimated parameters was reduced.
Because of the particular interest in the fate of serine, the model was used to estimate
whether serine is consumed in the gut, absorbed by the liver, or entered the blood in either
a free state, or in a protein- or tissue-bound state that is not measured by our assay. The
PK model structure was set up to represent relevant physiology, and this quantitative
systems biology approach allowed a broader set of physiological data to be used to
narrow parameter and prediction confidence intervals, and to better understand the
biological meaning of the data. The model results allowed us to determine the optimal
human dose for future trials, including a trial design component including IV and tracer
studies. A key contribution is that we were able to use human physiological data from the
literature to inform the PK model and to set reasonable bounds on parameters, and to
improve model conditioning. Leveraging literature data produced a more predictive,
useful model.
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INTRODUCTION
L-Serine (serine), a non-essential amino acid (AA), is de novo
synthesized from glucose via 3-phosphoglycerate/3-
phosphoserine and via interconversion of glycine. It can be
obtained from diet, the degradation of dietary proteins and
phospholipids and consumed in the production of pyruvate,
amino acids (glycine, L-cysteine), and sphingosine and
phosphatidyl serine. It also may be racemized to D-serine.
Serine has attracted interest in the treatment of
neurodegenerative diseases (de Koning et al., 2003), including
Amyotrophic Lateral Sclerosis (Levine et al., 2017) and
neuropathy (Garofalo et al., 2011; Scherer, 2011; Gantner
et al., 2019).
As shown in Figure 1 (after (de Koning et al., 2003)), serine
can be part of key metabolic pathways associated with proteins
and carbohydrates, and supplemental serine is expected to affect
hepatic metabolism. Mardinoglu et al have used Genome Scale
Metabolic (GEM) modeling to infer that supplementation of
serine may affect hepatic pathways that are relevant to the
pathology of non-alcoholic fatty liver disease and
steatohepatitis (NASH) (Mardinoglu et al., 2014).
Experimentally, a positive effect of serine therapy had been
reported for alcoholic fatty liver in mice and rats (Sim et al.,
2015). This led to a clinical trial of oral serine, showing a
significant reduction in hepatic fat (assessed via imaging) with
concurrent reduction of liver tissue fibrotic serum markers
(Mardinoglu et al., 2017). The trial data and further metabolic
modeling analysis was used to generate a more comprehensive
therapy approach, supplementation of metabolic cofactor
formulation, of which serine is one of the component
(described in Mardinoglu et al., 2017, 2019). Accurate
modeling of serine, accounting for endogenous production and
clearance, was needed to set the level of serine as part of this
therapeutic cocktail.
Here, we aim to identify the optimal human dose of serine in
this formulation to obtain the best therapeutic effect, and to avoid
adverse effects in future clinical trials. Understanding clinical data
and modeling the PK is complicated by the endogenous
production of serine, predominantly (perhaps solely) from the
kidney (Pitts and MacLeod, 1972; Kalhan and Hanson, 2012)
leading to a measurable and significant baseline level in the blood.
Review and Analysis of Literature Data
PLASMA METABOLOMICS ANALYSIS Measurement of
plasma levels of metabolites was performed using LC-MS.
Briefly, the liquid chromatography–tandem mass spectrometry
(LC-MS/MS) platform was based on a Waters ACQUITY
ultraperformance liquid chromatography (UPLC) system and a
Thermo-Finnigan LTQ mass spectrometer operated at nominal
mass resolution, which was equipped with an electrospray
ionization (ESI) source and a linear ion trap (LIT) mass
analyzer. The sample extract was dried and then reconstituted
in acidic or basic LC-compatible solvents, each of which
contained 12 or more injection standards at fixed
concentrations. One aliquot was analyzed using acidic positive
FIGURE 1 | Production (red line) and use (black lines) of L-serine in the body. Modified from (de Koning et al., 2003).
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ion-optimized conditions and the other was analyzed using basic
negative ion-optimized conditions in two independent injections
using separate dedicated columns (Waters UPLC BEH C18–2.1 ×
100 mm, 1.7 lm). Extracts reconstituted in acidic conditions were
gradient eluted using water and methanol containing 0.1% formic
acid, whereas the basic extracts, which were also eluted using
water/methanol, contained 6.5 mM ammonium bicarbonate. The
MS analysis alternated between MS and data-dependent MS/MS
scans using dynamic exclusion, and the scan range was from 80 to
1,000 m/z.
Published PK Analysis of Serine Is Sparse.
Data From the Literature Are Given Below
VOLUME OF DISTRIBUTION (Pitts and MacLeod, 1972)
reported values for volume of distribution of 199 and 360 L for
dogs weighing 20 and 28 kg (10 L/kg and 12.9 L/kg, respectively).
BASELINE CONCENTRATION A mean level (for five
subjects) of 1.12 (with SEM of 0.046) mg/100 ml, equivalent to
106 (4.3) umol/L was reported (Stein and Moore, 1954). These
authors also cite a baseline serine level of 1.2 mg/100 ml,
equivalent to 114 umol/L, as being reported (Kurt Schreier and
Plückthun, 1950). A baseline serine value of 0.97 (0.07) mg/
100 ml, or 92.3 (6.3) umol/L was reported (Frame, 1958). Neis
et al. (Neis et al., 2017), reported a value, measured in the radial
artery, of 97.2 (4.7) umol/L and a value from the renal vein of 130
(8.4) umol/L, a positive difference (that is, kidneys releasing
serine) of 32.8 umol/L. These data show the importance of
rigorous methodology and complete reporting of data. Using a
standard value for kidney blood perfusion of 1.2 L/m (Calzia
et al., 2005), and assuming that the assays capture all serine in the
blood, we can estimate the net endogenous renal release of serine
as approximately 4.2 mg/min or 252 mg/h from the kidney. A
much higher estimate, which incorporates more detail and,
estimates serine production to be 150 umol//kg/h (Kalhan and
Hanson, 2012), or about 1,100 mg/h. Those authors suggest the
possibility of an upregulation of serine production in the liver
(but not in the kidney) during isocaloric protein restriction.
Wilcox et al. (Wilcox et al., 1985), show a mean baseline level
of serine of approximately 131 (SD of 18.5 SD) ug/ml for
nonpsychotic control subjects. Interestingly, the baseline level
shown for psychotics was 202.6 (SD 38) ug/ml, a difference that
was reported as strongly significant (p < 0.0001). These
researchers determined an approximately 50% lower serine
hydroxy methyl transferase (SHMT) enzyme activity in
psychotic patients than in controls. The SHMT enzyme
cleaves serine in the pathway synthesizing glycine from serine.
Unfortunately, the order of magnitude for the baseline values
reported is inconsistent with other reports (131 ug/mL is about
1,247 umol/L, about 10 fold higher than other sources).
VARIABILITYDURINGTHEDAYDetailed analysis of other
amino acids show a time variation in concentration after meals in
pigs (Stoll et al., 1998), and a similar variation in human serine
production might be expected. Stoll also pointed out that 40% of
dietary serine was extracted by the liver in the first pass.
PK DATA/EXPERIMENTSWilcox et al. (Wilcox et al., 1985),
also administered an oral bolus of 4 mM/kg of serine to 12
actively psychotic patients, and 10 nonpsychotic subjects. This
is equivalent to about a 29.5 g dose, for a 70 kg subject. Using the
oral dosing data, they found a range for serine elimination half-
life of between 1.85 and 14.81 h presumably due, at least in part,
to SHMT level differences. There was a bimodal difference
between active or previously active psychotic patients, and
non-psychotic patients with no such history. The variability
for psychotic patients was also much larger than for
nonpsychotic subjects. The mean for non-psychotics was
approximately 3.23 h, with a standard error of the mean of
0.08 h. The differences reported in SHMT may cause the
longer half-life values and the higher baseline values. Clearly
these factors must be considered in safe serine dosing in psychotic
patients. Again the apparent discrepancy in units is noted.
PRODUCTION Endogenous production, at some level,
clearly must be represented in the model. An accurate PK
model must include physiological knowledge to some extent,
as it must account for endogenous serine and accurate serine
clearance. Indeed, because of the oral dose and the time-varying
nature of serine concentration, the use of mechanistic
understanding and literature data pertaining to parameters
with physiological meaning were necessary to fit and validate
our dosing model.
CLEARANCE MECHANISM The human kidney extracts
AAs (significantly, glutamine and glycine) and secretes other
amino acids (in largest amounts, serine and alanine) (Pitts and
MacLeod, 1972). Serine is extracted by the liver and other tissues
including skeletal muscle (Felig, 1975). Exercise does not appear
to affect serine concentration by more than five percent from the
mean (Felig andWahren, 1971). Glycine is the major precursor of
serine, but glycine uptake is not adequate to account for all serine,
and so glycolytic intermediates are also used by the body
(Brosnan, 2003).
Serine is extracted from the blood by the liver in two major
ways. There is a first pass clearance effect in which the liver
extracts orally dosed serine from the splanchnic circulation via
the portal vein. In piglets fed with a mix of amino acids (Stoll
et al., 1998) found that this first-pass metabolism in a fed state
amounted to 58% of ingested serine. They also found that
quantitatively more of the absorbed essential amino acids were
catabolized than were incorporated into peptides and proteins.
Hepatic extraction values for serine from arterial circulation of
24.1 and 55.0% were observed in rats receiving a 13% or 50%
casein diet (Remesy et al., 1983). In roosters, a hepatic extraction
value of 14% for serine was observed (Song et al., 2001).
In humans after 10–12 h fasting, It has been reported that the
small extraction of serine, that is the difference of 2.4 (5.1) umol/
liter difference between portal vein and arterial concentration,
was statistically insignificant (Felig and Wahren, 1971). In their
study, the reported arterial serine concentration was 110.0 11)
umol/liter.
The mode of liver serine uptake is extraction of serine from the
hepatic artery. Presumably this occurs in both fed and fasting
states. In humans, it has been showed (graphically) a drop
between arterial and hepatic vein concentrations of about
20 umol/liter, from a base of approximately 111 umol/liter in
resting, postabsorptive (12–14 h fast) state (Felig and Wahren,
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1971). Again, using a standard value for hepatic perfusion of
1.4 L/min (Calzia et al., 2005), this would amount to 28 umol/
minute, or 3 mg/min, or 180 mg/h.
There is also extraction by muscle tissue. It has been reported
that the arterio-femoral vein difference of serine for subjects in a
postabsorptive state (10–14 h fasting) to be 10.5 umol/liter with a
standard error of about 4 umol/liter, with the base arterial level to
be 110.0 ± 11 umol/liter (Felig andWahren, 1971). This work also
gave an estimate of total blood flow to the legs, which was 0.9
(SEM 0.05) L/min. However, if a standard value for specific blood
flow to muscle of 0.08 L/kg/min and the body is assumed to be
42% muscle, a 70 kg human will have muscle perfusion totaling
2.4 L/min (Calzia et al., 2005). If the serine extracted from all
muscle averages the same 10.5 umol/liter, this gives an
approximation of 25 umol/minute, or 2.6 mg/min, or 156 mg/h.
The fasting values of 4 mg/min released by the kidney, and 3
and 2.6 mg/min uptake into the liver and muscle, respectively, are
approximations but the values were used to check our model for
gross error.
TOXICOLOGY Garlick (Garlick, 2001) assessed hazards of
increased oral amino acid intake and noted that data were sparse.
Besides the paper by (Wilcox et al., 1985), which evaluated large
doses (nearly 30 g equivalent in a 70 kg subject) in 10 control and
12 psychotic subjects and noted no adverse effects, a study of four
actively psychotic schizophrenics by (Pepplinkhuizen et al., 1980)
found that administering 2 mmol/kg (which would be about 13 g
total, for a 60 kg subject) of serine to four female patients led to
depersonalization in all, dysperception in 3, and euphoria and
hallucination in one. Additional effects were noted. In all, the
effects occurred about 5 h after administration, and lasted 3–6 h.
None of the controls reacted to serine. This has implications
when administering serine to trial subjects or patients with high
baseline serine levels. It should be noted that serine does racemize
to its enantiomer D-serine, and that D-serine is being investigated
in schizophrenia – as a potential therapy (Kantrowitz et al., 2010,
2015), or as a therapy in combination with other therapies (Tsai
et al., 1998) (Heresco-Levy et al., 2005).
Doses of 0.5, 2.5, 7.5, and 15 g of serine were administered
twice a day in a trial with ALS (Amytrophic Lateral Sclerosis)
patients (Levine et al., 2017). While three of the 19 subjects died
during the trial, this was in line with expected mortality for the
cohort of ALS patients tested. Adverse effects which may be due
to serine included one withdrawal due to bloating in one 15 g b.
i.d. patient.
In sum, serine is a dietary component and even at fairly
elevated dosing (∼30 g/day) showed rew reported adverse
effects and those reported were minor.
The advantage of making our model “physiological,” in which
parameters such as serine biosynthesis rate correspond to a
physical reality, allowed us to check values against reported
values, and to constrain other (unreported) values.
RESULTS–CLINICAL TRIAL
The goal of the trial was to support optimal dosing for subsequent
trials and to support better insight from our other modeling
approaches, (e.g. GEM models of NAFLD and NASH, CITE).
There were previous trials with some results, and so this trial was
to improve quantitative understanding (for example of
endogenous serine production) previously reported.
Ten participants were recruited within the schedule
constraints imposed by the next trial and the number was
determined to be adequate for purpose. All subjects were
made aware of the risks inherent in the trial, and all agreed to
participate. The study was performed in accordance with the
Declaration of Helsinki and it was approved by the Ethics
Committee at the Koc University, Istanbul, Turkey. Each
subject gave written informed consent before participation in
the study. The clinical trial was registered at ClinicalTrials.gov
(with identifier: NCT03838822). Time limitations in recruiting
limited trial subjects to males (future trials will include both
sexes). One subject (subject 9) is a Type 1 diabetic and the other
subjects were generally healthy. One subject (subject 10) had
received the cocktail during the preceding two weeks, but that
subject’s results were unremarkable and very close to responses of
other subjects. Demographic data are summarized in Table 1.
The protocol covered five days. All dosing was oral, in the
morning after an overnight fast. On the first day, all subjects
received 1 g of nicotinamide riboside. On day two, all subjects
received 3 g of L-carnitine. On day three, all subjects received 5 g
of N-acetyl cysteine. On day four, all subjects received a “cocktail”
comprising the same dosing of NR, L-Carnitine, and NAC, and
20 g of serine. On day 5, a 20 g dose of serine alone was
TABLE 1 | Selected serine parameters.
Measurement Source Value (SEM) Species
Volume Pitts and Macleod. (1972) 10, 12.9 L/kg Dog
Baseline concentration in blood Stein and Moore. (1954) 106 (4.3) umol/L Healthy human
Kurt Schreier and Plückthun. (1950) 114 umol/L Healthy human
Frame. (1958) 92.3 (6.3) umol/L
Neis et al. (2017) 97.2 (4.7) umol/L Human (radial artery)
Neis et al. (2017) 130 (8.4) umol/L Human (renal vein)
Wilcox et al. (1985) 130.7 (18.5) ug/mLa Human
Half-life Wilcox et al. (1985) 3.23 (0.08) hrs Human
Production Estimated from neis data 252 mg/h Human
Kalhan and Hanson. (2012) 1,100 mg/h Human
aUnits appear to be incorrect in original.
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administered. Blood samples were taken every day (with number
of samples per day being 2, 2, 1, 8, and 1 for days 1–5,
respectively) to test the potential acute toxicity on human
health and evaluate the effect of different components in the
original clinical study (reported elsewhere (Zhang et al., 2020),
and only relevant samples were analyzed for serine in this study.
Note that the model parameter estimation included one serine
data point on day 5 to evaluate the clearance after 24 h of cocktail
supplementation.
Serine was supplied as a powder. 20 g doses were prepared by
weight and administered after mixing with 200 gr of water. There
were no adverse effects reported by the participants during the
trial. A trellis plot of the data for serine concentration over time is
shown Figure 2. It is clear that a non-zero baseline value for
serine is observed in all subjects. The average of the (pre-dose or
baseline) serine values was 117 (6.7) umol/L, consistent with
reported values given in the literature cited.
MODELING AND ANALYSIS
Figures 2A,B show the data on one plot, time-shifted so that the
first dose was at time zero. The model trace shown in the figures is
from a linear model, with mass action absorption of serine from a
gut compartment to a plasma compartment subject to a
bioavailability, mass action clearance from the plasma, and a
constant endogenous biosynthesis being added to the plasma
compartment. This is represented graphically in Figure 3. The
modeling equations used were as follows. First, the amount of
serine in the gut dose compartment, D, is.
dD
dt
 −kabsD + DoseAmt p δ(t − tDose) C (1)
Where d is the Dirac delta function and DoseAmt is the bolus
dose quantity.
The equation for Serine concentration, C, with five adjustable




 F kabs D + kgen − CL · C (2)
Where C denotes serine concentration, VD is the apparent
volume of distribution of serine, F is bioavailability, kabs is a
rate constant for absorption, kgen denotes a constant endogenous
serine production rate, CL is serine clearance.
One modeling assumption that should be highlighted is that
endogenous serine production is assumed constant. One conclusion
is that the administered dose of serine is virtually cleared within 12 h.
Note that without a pre-existing value for the volume of
distribution or bioavailability, this form of equation is usually
poorly conditioned and any set of parameters (VD, F, kabs, kgen,
FIGURE 2 | Plots of data, time-shifted so that the initial dose time is 0 h. This resulted in the second dose time varying between 25.3 and 26.3 h, shown as a
horizontal bar in figures. A naïve pooledmodel (dashed black line) is plotted with the individual data (colored dots and solid lines). (A) Linear plot. (B)Semi-logarithmic plot.
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and CL) that fits data could be scaled by an arbitrary amount to fit
the data equally well. Nonetheless, a least-squares fitting process
using naïve pooled technique did converge to a volume of about
1 L.We know that this is likely not correct, as (Pitts andMacLeod,
1972) estimated volumes for dogs of approximately 160 L.
Parameter values are shown in Table 2. The individual data,
and the naive pooled model results are plotted in Figures 2A,B.
The terminal clearance coefficient (CL/VD, i.e., the rate of
endogenous generation) is 0.48/hr. This is equivalent to a half-life
of 1.45 h, a bit lower than reported by (Wilcox et al., 1985). The
rate of endogenous generation is calculated (CL * baseline) as
6.6 mg/h, significantly lower than discussed above. This assumes
a volume of distribution of about 1 L, though, which is
significantly at odds with the 199 and 260 L values for dogs
cited by (Pitts and MacLeod, 1972).
In addition to the non-physiological value for volume, the
previous fit uses a naïve pooled-date approach and hence does not
represent any subject very well, as the averaging process distorts
absorption and clearance parameters and yields unrepresentative
values for, for example, predicted maximum concentration, or
Cmax. This motivated the use of population modeling.
The model may be modified to improve conditioning and to
allow more detailed representation of the physiology discussed
above so as to allow the use of a wider range of data. Also, one
desired use for the model was to simulate clinical trials. Models
that represent an average patients, but not any individual patient
are not adequate for these tasks.
Model fitting without prior knowledge of volume (or
bioavailability) will require modification to equation 2 to









This reduces the degrees of freedom by one, as the fitting must
solve only for four adjustable constant parameters (F/VD, kabs,
kgen/VD and CL/VD).
FIGURE 3 | Graphical model representation from SimBiology(R).
TABLE 2 | Trial subject demographic data.
N = 10 Weight (kg) Height (cm) Bmi
Mean 82.8 177.0 26.4
Std dev 16.5 8.3 4.5
Median 78.9 175.0 25.3
Minimum 61.0 166.0 19.4
Maximum 114.8 192.5 34.5
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To generate parameter estimates and distributions, and to
understand parametric distribution and confidence intervals for
model prediction, we proceeded to use population
pharmacometric approaches to modeling (Mold and Upton,
2013; Owen and Fiedler-Kelly, 2014; Upton and Mold, 2014,
2014).
The model was first implemented in SimBiology (MathWorks
Inc., Natick MA, United States). SimBiology allows a graphical
approach to model building. The picture of the model has
underlying mathematics, and fitting and data manipulation
can be done using integrated software. The model is pictured
in Figure 3.
FIGURE 4 | Time vs concentration data and fitted results. Each plot is an individual’s data. The range of concentrations (vertical lines) are from 0 to 1,000 umol/L.
Each subject was fitted individually, using a nonlinear least-squares routine with combined (constant plus proportional) error model in SimBiology
®
. Clinical data (+) and
model simulation (line).
TABLE 3 | Naive pooled fitted parameters for the poorly conditioned model shown in Figures 2A,B.
Dose Ka F CL Baseline V
- Absorption Bioavailability Clearance Concentration Volume
20 0.829 0.00452 0.446 1.474 0.936
g 1/hour Dimensionless L/hour mg/100 ml liter
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Before applying population methods, a first step in fitting this
model was to fit each subject individually. This was done using
the nonlinear least-squares (lsqnonlin) routine. The mixed
(constant plus proportional) error model was found to give
the best results. The results are shown in Figure 4 and
parameter estimates are given in Table 3.
Again, the mean values given cannot be guaranteed to actually
represent any individual. That is, using these parameters in a
simulation may result in an outcome that is not physiologically
feasible or reasonable. Furthermore, the method used gave a
physiologically unreasonable volume of distribution, due to the
absence of iv data for serine administration. We could find no
such data. So in subsequent fits we estimated ratios (CL/V, for
example). A way to achieve mean parameters that are
representative is to use a population approach. The nlmefit
(non-linear mixed effect modeling) routine in SimBiology
(MathWorks Inc., Natick, MA) was used using a combined
(constant plus proportional) error model. The approach
yielded the fits shown below:
The resulting parameters are given in Table 4. What is striking
is just how small the variabilities for several parameters are. Most
of the variability is in the bioavailability (F/V) parameter. The
parameters were estimated as following a lognormal distribution,
and so the parameter values estimated as the natural logarithm of
the parameter, with standard errors are in logarithmic terms. To
give ranges in meaningful units, the exponential of the nominal
value and the nominal value plus and minus one standard error
were calculated. Model results are plotted in Figure 5.
To check these results, the same model was programmed in
NONMEM® (ICON Plc, Ellicott City, MD). Parameter
distribution was implemented as lognormal. The proportional
error model gave nearly the same results as the mixed model, and
so proportional error was used. The results for the proportional
error model are given in Table 5.
The Eta values that are shown as small were so small as to not
allow noticeable variability (no change in three significant figures)
and could be fixed in the estimation scheme (Figure 6; Table 6). We
note that the variability in the NONMEM parameters yields
TABLE 4 | Parameters from individual fit.
Kabs F/VD x 1,000 CL/VD kgen/VD
Mean 4.67 4.94 0.346 35.8
Std dev 3.33 0.96 0.087 11.0
Minimum 0.51 3.47 0.198 20.6
Maximum 15.6 6.51 0.505 54.5
Units 1/hour 1/Liter 1/hour Umol/(hr*liter)
FIGURE 5 | Results for Clinical data (+) and model simulation (line). Time vs concentration data and fitted results. Each plot is an individual’s data. The range of
concentrations (vertical lines) are from 0 to 1,000 umol/L. All subjects fit using a population methods and a combined (constant plus proportional) error model in
SimBiology®. Clinical data (+) and model simulation (line).
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qualitatively different result than observed with nlmefit. One
plausible explanation is that the two approaches found different
local minima (Ricardo Paxson and Florian Augustin of MathWorks
Inc., personal communication) as parameter variance estimates in
nlmefit initially are set to zero, while in NONMEM®, these values
may be initialized via the OMEGA vector or matrix.
We evaluated whether a second compartment improved the
model. The improvement in the log-likelihood-based NONMEM
metric (967.5 vs 979.785 for the one compartment model) lead to
a difference of 12.2 which is more than the threshold of 5.99
(Fisher and Shafer, 2007) and would justify the addition of two
additional parameters (rate-law constants k23 and k32).
However, the fitted value of these parameters were four orders
of magnitude less than clearance and absorption rate constants
and resulted in other parameter estimates changing only in the
third decimal place with a change in predicted values that was
trivial in relation to serine concentration. The additional
compartment complexity was rejected on this basis.
We evaluated weight and height as potential covariates. Of the
two parameters that showed variation between subjects, neither
was shown to be correlated in any way to either metric. Likewise,
there were no meaningful trends observed between other metrics
(e.g. residual values) and weight and height. Our final model did
not include covariates.
DISCUSSION
By using a model that was consistent with physiology, a broad
range of published data for serine was able to be exploited. Model
structure was improved, and we were able to build confidence in
some fitted parameters (such as endogenous production rate).
Animal extraction data (Neis et al., 2017) were used to estimate
bioavailability (∼60%) and ultimate hepatic serine uptake fraction
(75%). We were able to reject reported volume of distribution
values from animal data (Pitts and MacLeod, 1972) as
inappropriate for scaling to humans. Without intravenous
data, a value for volume of distribution was estimated for
serine (∼140 L).
The dosing of 20 g QD in normal patients did not elicit any
adverse effects in our clinical trial. The work of Wilcox et al.
(Wilcox et al., 1985) noted no adverse effects in normal and
psychotic subjects for a dose of 4 mM/kg, which is equivalent to
0.424 g/kg, or a 29.7 g dose for a 70 kg subject. Wilcox et al.
(Wilcox et al., 1985) did note a higher baseline serine value, and
lower SHMT activity, in psychotic subjects, and (Pepplinkhuizen
et al., 1980) did observe schizophrenia-like psychoses induced in
TABLE 5 | Parameters from population fit using SimBiology® nlmefit with
proportional error model.
Kabs F/VD x 1,000 CL/VD kgen/VD
Population 2.88 4.29 0.288 29.6
Pop—SEM 1.88 3.96 0.266 27.0
Pop +SEM 4.42 4.64 0.312 32.3
Minimum 2.88 3.47 0.288 29.6
Maximum 2.89 4.87 0.288 29.6
Units 1/hour 1/Liter 1/hour Umol/(hr*liter)
FIGURE 6 | A) (above) Box and whisker plot of estimated parameters from population fit. Most variability is in the F/VD parameter. B) (at right) Plot of residuals to
evaluate normality using a combined (constant plus proportional) error model. The combined model gave improved normality in the “tails” at both low and high values
shown here, as opposed to a constant error model.
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four active female schizophrenics (2 mM/kg, or 0.212 g/kg,
equivalent to 12.7 g dose in a 60 kg women). This suggests,
but does not prove, that a dose of 20 g or less may be
tolerated in those who are not actively psychotic. Given that
biopsy and/or tracer studies for SHMT activity are intrusive, a
baseline serine value should be considered as an inclusion/
exclusion test for future trials.
With that said, the 75% overall hepatic extraction with a 20 g
dose is equivalent to 15 g absorbed by the liver. Averaging this
over 24 h yields 10.4 mg/min – a bit more than twice the current
value of endogenous production, from clinical measurements.
Thus, a 20 g daily dose is expected to approximately triple hepatic
serine uptake. Alternately, an approximately 12 g dose twice a day
could be considered, due to the quick clearance of serine.
Systems modeling allowed the use of a broader set of data to
expand our understanding of trial results. Reported parameters
were used to rule out our first naïve pooled model, and to bound
parameters in our population PK model. The population PK
model was then used to inform our dosing decision for an
upcoming trial. The modeling also highlighted the need to
determine volume of distribution and bioavailability.
What was not considered was the variation of serine release
and uptake during the day. We believe that this variability is
inconsequential for our purpose of dose-setting, but the model
could be augmented should this variation be relevant. We did not
include the extraction of serine by the brain, but this could be
easily analyzed using a modification of the current model and
relevant trial data, for example using the results of (Levine et al.,
2017), and a completed trial of serine in neuropath (Fridman
et al., 2019).
A key interest in dose determination for serine is estimating
the amount absorbed by the liver. Hepatic extraction will be both
first-pass, from splanchnic circulation into the hepatic portal
vein, and also system extraction from arterial circulation.
Supposing that the 24.1 or 55 percent extraction range
observed by (Remesy et al., 1983) in rats applies to humans,
and assuming other use (for example, bacterial consumption in
the gut) is negligible, this would imply a standard oral
bioavailability values of 75.9 and 45%. Using the fitted value
for F/V of 0.00429 gives values of volume of distribution of 177
and 104 L. The question is whether these numbers and ranges are
physiological.
It has been reported that the values for volume of distribution
of 199 and 360 L for dogs weighing 20 and 28 kg (10 L/kg and
12.9 L/kg, respectively, must be scaled (Pitts and MacLeod, 1972).
One source gives blood volume in dogs as 79 ml of blood per kg of
body weight (Courtice, 1943). From this, we can calculate blood
volume estimates of 1.580 and 2.212 L. Allometric scaling
principles suggest that these values might be scaled
proportionally to body weight (Holford and Anderson, 2007),
yielding (for both dogs) a value of about 5.5 L of blood for a 70 kg
human, only about 10% higher than the commonly used value of
5 L. The volume of distributions from dogs can be scaled
proportionally to weight, yielding 700 and 900 L. Using the
average value of 800 L, and 0.00429 for F/V gives an infeasible
bioavailability of 340%. This suggests that the volume of
distribution of serine reported for dogs (Pitts and MacLeod,
1972) is not appropriate or useful for humans, or at least that
allometric scaling was not correct. Because of this, and because we
suspect that extraction may be a more intrinsically conserved
between species, the hepatic extraction values reported in rats
(Remesy et al., 1983) were used to generate bioavailability. A
bioavailability of about 0.6 (roughly the average between the
0.759 and 0.45 values in rats) yielded an effective volume of
distribution of about 140 L.
Of key interest is the fate of the approximately 60% of serine
that is not initially absorbed by the liver. Recall the estimate above
that the liver consumed about 3 mg/min, and the muscle tissue
about 2.6 mg/min. Assuming that these are the major consumers
of arterial serine yields an estimate of arterial serine clearance of
46% by muscle and 54% by the liver. These values suggest that the
liver extracts about 73% (40% initially, and another 46% of the
60% of serine that ends up in plasma) of ingested serine, with the
rest going to muscle. This number is probably high, as some of the
arterial serine is likely extracted by tissues other than muscle.
The population fit of endogenous serine generation was
estimated to be 29.6 umol/L/hr, as kgen/V. When multiplied
by the estimated volume of 140 L, this gives 440.0 mg/h. This
must be compared with the 252 mg/h estimated from (Neis et al.,
2017), and the 1,110 mg/h estimated from the work of (Kalhan
and Hanson, 2012) which was felt to be high. Given differences in
protocols, subjects, and variability of measurements, these value
does not compare unfavorably, and provide some confidence in
the model analysis.
If 440 mg is generated endogenously every hour, and the liver
accounts for the uptake of 54% of that amount, normal liver
uptake of serine is about 6 g of serine per day. An oral dose of 8 g/
day (6 g/73% liver utilization for oral dosing) could
approximately double liver uptake, and a dose of 16 g/day
could be expected to triple liver uptake, provided the
extraction values considered here did not change. Earlier
experiments with once-per-day 20 g dosing (Mardinoglu et al.,
2017) gave good results in some subjects, weaker responses in
others. Noting that daily dosing up to about 30 g have been
administered to normal subjects without adverse effects, and
desiring a stronger effect suggested that a prudent upper bound
would be a total of 25 g per day. Given that the serine is apparently
cleared quickly and a sustained metabolic effect is desired, the
recommended 25 g dose could be administered as 12.5 g, twice a
day. This was the recommendation for the upcoming trial. A more
comprehensive clinical trial is planned and will be executed. A
portion of that trial will include intravenous dosing to allow a better
determination of bioavailability. In addition, we expect to use tracer
studies to confirm hepatic extraction values derived from the model.
We have fit new serine data to a model representing
physiology (serine synthesis and clearance). The parameters of
TABLE 6 | Population fit parameters from NONMEM.
Kabs F/VD x 1,000 CL/VD kgen/VD
Population 2.75 4.58 0.312 32.1
Eta value 0.921 Small (FIXed) 0.0135 Small (FIXed)
Units 1/hour 1/Liter 1/hour Umol/(hr*liter)
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the model correspond to physiological quantities, allowing
comparisons and building confidence in the model, the methods
used, and the data reported. The generally good fit of the model built
confidence in structure and fitted parameters, while the agreement
between the model parameters and reported values of physiological
constants gave additional model validation. The dose determined
using the model was selected for future trials.
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